Dupixent
Overview
- Drug Brand Name: Dupixent
- Active moiety or active ingredient: dupilumab
- Application Number: BLA761055
- Duxpient NDC 11s in the Cost Review Study Process - PDF - 86.75 KB
Dupixent Cost Review Study Process
Dupixent was selected for Cost Review by the Board on May 20, 2024.
Relevant Information:
The 60 day comment period was posted on May 2, 2024 and comments were accepted until July 22, 2024.
Relevant Information:
Comments received on Dupixent during the 60 day comment period. - PDF - 511.65 KB
The request for information for Dupixent was distributed/posted on May 28, 2025. For each prescription drug product under review, the Board may request the following information from: Manufacturer, Health Insurance Carrier, HMO, and MCO, Pharmacy Benefit Managers, and Wholesale Distributors.